Experimental vaccine combo aims to shrink throat tumors and cut radiation dose
NCT ID NCT05108870
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 25 times
Summary
This study tests whether adding experimental drugs HB-201 and HB-202 to standard chemotherapy can shrink HPV16-positive throat tumors more effectively. The goal is to reduce the amount of radiation and chemotherapy needed afterward, potentially lowering side effects. About 35 adults with HPV16-positive oropharyngeal cancer will participate for around 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.